Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Other Non-Current Assets (2023 - 2025)

Telix Pharmaceuticals has reported Other Non-Current Assets over the past 3 years, most recently at $28.8 million for Q4 2025.

  • Quarterly Other Non-Current Assets rose 79.31% to $28.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.8 million through Dec 2025, up 79.31% year-over-year, with the annual reading at $28.8 million for FY2025, 91.0% up from the prior year.
  • Other Non-Current Assets was $28.8 million for Q4 2025 at Telix Pharmaceuticals, up from $16.1 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $28.8 million in Q4 2025 and troughed at $381480.4 in Q4 2023.
  • The 3-year median for Other Non-Current Assets is $16.1 million (2024), against an average of $15.1 million.
  • Year-over-year, Other Non-Current Assets soared 4113.99% in 2024 and then surged 79.31% in 2025.
  • A 3-year view of Other Non-Current Assets shows it stood at $381480.4 in 2023, then soared by 4113.99% to $16.1 million in 2024, then surged by 79.31% to $28.8 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Other Non-Current Assets are $28.8 million (Q4 2025), $16.1 million (Q4 2024), and $381480.4 (Q4 2023).